Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida  by Pfaller, M.A. & Diekema, D.J.
Twelve years of ﬂuconazole in clinical practice: global trends in species
distribution and ﬂuconazole susceptibility of bloodstream isolates
of Candida
M. A. Pfaller1,2,3 and D. J. Diekema1,2for the International Fungal Surveillance Participant Group
Departments of 1Pathology, 2Medicine and 3Epidemiology, Roy J. and Lucille A. Carver College of
Medicine and College of Public Health, University of Iowa, Iowa City, IA 52242, USA
ABSTRACT
We determined the species distribution and in-vitro susceptibility of 6082 bloodstream infection (BSI)
isolates of Candida spp. collected from 250 medical centres in 32 nations over a 10-year period from 1992
through 2001. The species included 3401 C. albicans, 984 C. glabrata, 796 C. parapsilosis, 585 C. tropicalis,
153 C. krusei, 67 C. lusitaniae, 48 C. guilliermondii, 10 C. famata, 10 C. kefyr, six C. pelliculosa, ﬁve C. rugosa,
four C. lipolytica, three C. dubliniensis, three C. inconspicua, two C. sake and one isolate each of C. lambica,
C. norvegensis and C. zeylanoides. Minimum inhibitory concentration determinations were made using
the National Committee for Clinical Laboratory Standards reference broth microdilution method.
Variation in the rank order and frequency of the different species of Candidawas observed over time and
by geographic area. The proportion of BSI due to C. albicans and C. glabrata increased and C. parapsilosis
decreased over time in Canada, the USA and Europe. C. glabrata was an infrequent cause of BSI in Latin
America and the Asia-Paciﬁc region. Very little variation in ﬂuconazole susceptibility was observed
among isolates of C. albicans, C. tropicalis and C. parapsilosis. These species accounted for 78% of all BSI
and remained highly susceptible (91–100% susceptible) to ﬂuconazole from 1992 to 2001 irrespective of
geographic origin. The prevalence of ﬂuconazole resistance among C. glabrata isolates was variable both
over time and among the various countries and regions. Resistance to ﬂuconazole among C. glabrata
isolates was greatest in the USA and varied by US census region (range 0–23%). These observations are
generally encouraging relative to the sustained usefulness of ﬂuconazole as a systemically active
antifungal agent for the treatment of candida BSI.
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INTRODUCTION
Candidemia is without question the most import-
ant of the invasive mycoses [1]. It is estimated that
bloodstream infection (BSI) due to Candida spp.
occurs at a rate of 0.5–10 infections per 1000
hospital admissions and accounts for 8–10% of all
nosocomial BSI [2–5]. Population-based studies
conducted in the USA estimate an annual inci-
dence of 6–10 episodes of candidemia per 100 000
population [6–9]. This relatively high incidence,
plus an excess mortality of approximately 38%
[10], makes BSI due to Candida spp. an important
public-health problem [1].
Treatment of candidemia over the past decade
has been enhanced considerably by the introduc-
tion of ﬂuconazole in 1990 [11,12]. The absence of
toxicity, ease of administration, and documented
efﬁcacy in treatment of candidemia have resulted
in extensive usage of ﬂuconazole in most areas of
the world [11–15]. Because of this widespread
usage, concern about the possible development of
ﬂuconazole resistance among Candida spp.
abounds [15–21]. Fluconazole resistancehas clearly
been documented among Candida spp. isolated
from patients with acquired immune deﬁciency
syndrome who have recurrent oropharyngeal
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candidiasis [19,22–24]; however, it is relatively
uncommon among most species causing BSI
[8,11,17,25–27]. The exception to this statement is
C. glabrata, of which ‡ 10% of BSI isolates may be
highly resistant to ﬂuconazole [6,8,9,28–31]. Sub-
optimal ﬂuconazole dosing practices [low dose
(< 400 mg ⁄day), poor indications] may lead to an
increased frequency of isolation of C. glabrata as
an aetiological agent of candidemia in hospital-
ised patients [30,32,33] and possibly to increased
ﬂuconazole (and other azole) resistance secondary
to induction of CDR efﬂux pumps [21,29,30,34].
Given these concerns, surveillance of candida BSI
to detect changes in species distribution and
susceptibility to ﬂuconazole on a regional, na-
tional and international scale is warranted
[30,35,36].
One of the important aspects of any anti-
microbial resistance surveillance programme is
longitudinality [27,30,37,38]. By conducting sur-
veillance of speciﬁc pathogens over time one can
assess the emergence of speciﬁc strains [39,40] or
species [27] and also detect changes in the
antimicrobial susceptibility proﬁle of the organ-
isms [30,37]. Furthermore, when longitudinal
surveillance encompasses a broad geographic
distribution, one may eventually develop a useful
picture of regional, national or even global trends
in species distribution and antimicrobial resist-
ance [30,37,38].
The number of surveillance programmes that
focus on candidemia has increased in recent years
[30]. These programmes have generated import-
ant information concerning the emergence, or
absence thereof, of Candida species other than
C. albicans, as well as antifungal susceptibility
data determined by standardised testing methods
[20,30]. Unfortunately, most programmes have
not been functional long enough to provide
longitudinal data that also encompasses isolates
from diverse geographic settings [30]. At the
University of Iowa we have conducted surveil-
lance of candida BSI using a consistent protocol
(consecutive incident BSI isolates, one per patient,
multiple institutions) and standardised reference
quality identiﬁcation and antifungal susceptibility
testing methods from 1992 up to the present
[30,33]. This cumulative experience allows us to
examine changes in species distribution and
in-vitro susceptibility to ﬂuconazole of candida
BSI isolates spanning a 10-year period and repre-
senting 250 medical centres in 32 nations.
CANDIDA BLOODSTREAM
INFECTION SURVEILLANCE
AT THE UNIVERSITY OF IOWA
Organism collection
A total of 6082 BSI isolates of Candida spp. from
250 medical centres in 32 nations were submitted
to the University of Iowa College of Medicine
(Iowa City, IA, USA) for identiﬁcation and anti-
fungal susceptibility testing of ﬂuconazole bet-
ween 1992 and 2001. The number of isolates
submitted each year ranged from 133 to 2770
(Table 1). The isolates represented consecutive
incident isolates from patients with candidemia
Table 1. Species distribution of candida bloodstream isolates by year: 1992–2001a
Species
% of isolates by year
1992 1993 1995 1996 1997 1998 1999 2000 2001 All years
No. tested 235 315 332 133 413 328 320 1236 2770 6082
C. albicans 44.3 45.4 53.3 52.6 54.0 55.2 54.7 54.4 59.8 55.9
C. glabrata 16.6 14.0 20.5 15.8 15.3 17.7 15.3 15.3 16.4 16.2
C. parapsilosis 21.7 24.4 9.0 10.5 18.9 14.3 10.3 13.8 10.7 13.1
C. tropicalis 11.9 12.4 11.4 15.8 7.0 8.5 11.9 11.8 7.9 9.6
C. krusei 2.6 1.3 4.2 3.0 1.7 1.2 2.8 2.5 2.7 2.5
C. lusitaniae 2.1 0.6 0.6 0.0 0.0 0.6 2.2 1.1 1.3 1.1
C. guilliermondii 0.4 1.3 0.4 0.0 1.9 2.1 0.9 0.4 0.6 0.8
Other spp.b 0.4 0.6 0.6 2.3 1.2 0.4 1.9 0.7 0.6 0.8
aIncludes the following geographic areas: Asia-Paciﬁc (441 isolates), Europe, including Israel and Turkey (775 isolates),
Latin America (560 isolates), Canada (623 isolates), and USA (3683 isolates).
bIncludes C. famata (10 isolates), C. kefyr (10 isolates), C. pelliculosa (six isolates), C. lipolytica (four isolates), C. rugosa (ﬁve
isolates), C. dubliniensis (three isolates), C. inconspicua (three isolates), C. sake (two isolates) and one isolate each of C. lambica,
C. norvegensis and C. zeylanoides.
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cared for at hospitals in the following geographic
regions (Table 2): Asia Paciﬁc (441 isolates from
17 sites), Europe, including Israel and Turkey (775
isolates, 40 sites), Latin America (560 isolates, 18
sites), Canada (623 isolates, eight sites) and the
USA (3683 isolates, 167 sites). The US contributing
sites represented all nine US Bureau of the Census
regions (Table 3 and Fig. 1): region 1, Paciﬁc (439
isolates); region 2, Mountain (261 isolates); region
3, West North Central (302 isolates); region 4,
West South Central (162 isolates); region 5, East
North Central (376 isolates); region 6, East South
Central (94 isolates); region 7, New England (83
isolates); region 8, Mid-Atlantic (736 isolates); and
region 9, South Atlantic (1230 isolates). The
isolates included C. albicans (3401 isolates),
C. glabrata (984 isolates), C. parapsilosis (796 iso-
lates), C. tropicalis (585 isolates), C. krusei (153
isolates), C. lusitaniae (67 isolates), C. guilliermondii
(48 isolates), C. famata (10 isolates), C. kefyr (10
isolates), C. pelliculosa (six isolates), C. lipolytica
(four isolates), C. rugosa (ﬁve isolates), C. dublini-
ensis (three isolates), C. inconspicua (three isolates),
C. sake (two isolates) and one isolate each of
C. lambica, C. norvegensis and C. zeylanoides. All
isolates were identiﬁed by Vitek and API
Table 2. Species distribution of candida bloodstream isolates by geographic area: 1992–2001
Area
No.
sites
No.
isolates
% Isolates by species
CA CG CP CT CK Othera
Asia-Paciﬁc 17 441 73.5 10.2 8.4 3.9 3.2 0.8
Australia 4 44 65.9 6.8 15.9 4.6 6.8 0.0
China 2 28 50.0 21.4 3.6 21.4 0.0 3.6
Japan 1 2 100.0 0.0 0.0 0.0 0.0 0.0
Malaysia 1 35 28.6 5.7 48.6 14.3 2.8 0.0
Singapore 1 1 0.0 100.0 0.0 0.0 0.0 0.0
S. Africa 8 331 81.3 10.0 3.6 1.2 3.0 0.9
Europe 40 775 57.6 12.9 14.1 7.5 3.4 4.5
Austria 1 4 100.0 0.0 0.0 0.0 0.0 0.0
Belgium 1 10 70.0 10.0 10.0 0.0 0.0 10.0
Czech Republic 2 46 78.3 6.5 4.4 6.5 4.3 0.0
France 5 83 60.2 20.5 3.6 6.0 7.2 2.5
Germany 4 73 45.2 24.7 16.4 8.2 1.4 4.1
Greece 1 4 75.0 25.0 0.0 0.0 0.0 0.0
Ireland 1 1 100 0.0 0.0 0.0 0.0 0.0
Israel 1 86 45.4 9.3 18.6 22.1 1.2 3.4
Italy 7 99 69.7 7.1 11.1 5.1 2.0 5.0
The Netherlands 2 30 56.7 23.3 10.0 6.7 0.0 3.3
Poland 1 3 0.0 0.0 33.3 33.3 0.0 33.4
Portugal 1 28 42.9 14.3 21.4 10.7 3.6 7.1
Slovakia 1 22 68.2 9.1 9.1 0.0 13.6 0.0
Spain 3 86 47.7 16.3 24.4 2.3 3.5 5.8
Sweden 1 9 77.8 11.1 11.1 0.0 0.0 0.0
Switzerland 1 29 79.3 13.8 0.0 6.9 0.0 0.0
Turkey 3 150 55.3 6.7 18.7 6.7 4.0 8.6
UK 4 12 50.0 25.0 16.7 0.0 8.3 0.0
Latin America 18 560 46.6 7.5 17.7 21.3 3.6 3.3
Argentina 4 79 43.0 6.3 27.9 21.5 0.0 1.3
Brazil 6 279 44.8 7.5 20.4 21.5 2.9 2.9
Chile 2 82 61.0 12.2 9.8 13.4 0.0 3.6
Colombia 2 9 33.3 0.0 22.2 33.3 0.0 11.2
Mexico 3 13 53.8 0.0 30.8 15.4 0.0 0.0
Venezuela 1 98 42.9 6.1 6.1 25.6 12.2 6.2
Canada 8 623 58.9 20.1 10.3 5.9 2.4 2.4
USA 167 3683 54.4 18.3 13.2 9.6 2.1 2.4
Total 250 6082 55.9 16.2 13.1 9.6 2.5 2.7
aIncludes C. famata (10 isolates), C. kefyr (10 isolates), C. pelliculosa (six isolates), C. lipolytica (four isolates), C. rugosa (ﬁve
isolates), C. dubliniensis (three isolates), C. inconspicua (three isolates), C. sake (two isolates) and one isolate each of C. lambica,
C. norvegensis, and C. zeylanoides.
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products (bioMerieux, St Louis, MO), supplemen-
ted by conventional methods as required [41], and
were stored as water suspensions until they were
used. Prior to testing, each isolate was passaged at
least twice on potato dextrose agar (Remel,
Lenexa, KS) to ensure purity and viability.
Antifungal susceptibility studies
Broth microdilution testing was performed in
accordance with the guidelines in National Com-
mittee for Clinical Laboratory Standards (NCCLS)
document M27-A [42]. Fluconazole was obtained
from the manufacturer (Pﬁzer Pharmaceutical
Group, New York, NY) as a standard reagent
grade powder. The ﬁnal concentrations of ﬂucon-
azole ranged from 0.12 to 128 lg ⁄mL. The trays
were incubated in air at 35 C and minimum
inhibitory concentration (MIC) endpoints were
read after 48 h incubation.
Following incubation, the broth microdilution
wells were read with the aid of a reading mirror;
the growth in each well was compared with that
of the growth control (drug-free) well. The MICs
of ﬂuconazole were deﬁned as the lowest concen-
tration that produced a prominent decrease in
turbidity (approximately 50% reduction in
growth) compared with that of the drug-free
control [42]. The interpretive criteria for ﬂucon-
azole were those published by Rex et al. [43] and
the NCCLS [42]: susceptible (S), MIC £ 8 lg ⁄mL;
susceptible-dose-dependent (S-DD), MIC 16–
32 lg ⁄mL; resistant (R), MIC ‡ 64 lg ⁄mL.
GLOBAL TRENDS IN SPECIES
DISTRIBUTION AND FLUCONAZOLE
SUSCEPTIBILITY AMONG CANDIDA
BSI ISOLATES
Temporal and geographic inﬂuences on species
distribution in candidemia
Temporal distribution
Among the 6082 isolates of Candida submitted for
testing from 1992 to 2001, 55.9% were C. albicans,
16.2% were C. glabrata, 13.1% were C. parapsilosis,
9.6% were C. tropicalis, 2.5% were C krusei, and
2.7% were miscellaneous Candida species (Ta-
ble 1). The rank order of the different species
varied slightly over time, although C. albicans
was the predominant species in each year.
C. parapsilosis was the most common non-albicans
species in 1992 (21.7%) and 1993 (24.4%); how-
ever, the overall frequency of this species as a
cause of BSI decreased to 9% in 1995 and, with
the exception of 1997 (18.9%), remained less than
Table 3. Species distribution of candida bloodstream isolates in each of the nine US Bureau of the Census regions
Species
% of isolates by US census region
1 2 3 4 5 6 7 8 9 All
No. tested 439 261 302 162 376 94 83 736 1230 3863
C. albicans 48.7 64.5 60.6 56.8 47.6 61.7 47.0 51.1 56.4 54.4
C. glabrata 18.5 15.3 18.9 11.7 26.3 18.0 37.3 18.8 15.5 18.3
C. parapsilosis 18.5 4.6 7.6 13.6 10.7 4.3 9.7 17.1 13.9 13.2
C. tropicalis 9.6 8.8 10.6 9.9 9.3 11.7 4.8 8.7 10.3 9.6
C. krusei 2.5 1.1 0.7 5.6 3.7 4.3 1.2 1.9 1.6 2.1
C. lusitaniae 1.6 2.7 0.9 1.2 2.4 0.0 0.0 1.2 0.9 1.3
C. guilliermondii 0.6 1.5 0.0 0.0 0.0 0.0 0.0 0.5 0.5 0.5
Other speciesa 0.0 1.5 0.7 0.6 0.0 0.0 0.0 0.7 0.9 0.6
aIncludes C. famata (10 isolates), C. kefyr (10 isolates), C. pelliculosa (six isolates), C. lipolytica (four isolates), C. rugosa (ﬁve
isolates), C. dubliniensis (three isolates), C. inconspicua (three isolates), C. sake (two isolates) and one isolate each of C. lambica,
C. norvegensis, and C. zeylanoides.
Fig. 1. Map indicating the nine US Bureau of the Census
regions.
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15% throughout the remainder of the study
period. C. glabrata accounted for between 14.0%
and 20.5% of BSI during the 10-year period and
although there was no demonstrable trend to-
wards an increase in the overall percentage of BSI
due to this species over time, it rose from the third
most common BSI isolate in 1992 and 1993 to the
second most common from 1995 through 2001.
The frequency of C. tropicalis and C. krusei as BSI
isolates did not show any trend towards an
increase or decrease over time. Notably, the
overall frequency of C. krusei as a cause of BSI
remained low at 2.5% (range 1.2–4.2%) for the 10-
year period.
Geographic distribution
The frequencies of BSI due to the various species
of Candida in the different geographic areas are
shown in Table 2. The frequency of C. albicans as a
cause of BSI ranged from 46.6% in Latin America
to 73.5% in the Asia-Paciﬁc region. Within each of
the major geographic areas the frequency of BSI
due to C. albicans varied considerably, ranging
from 28.6% (Malaysia) to 81.3% (South Africa) in
the Asia-Paciﬁc region, from 45.2% (Germany) to
79.3% (Switzerland) in Europe, and 33.3%
(Colombia) to 61.0% (Chile) in Latin America.
Over the 10-year period the frequency of C.
albicans increased from 44% to 58% in the USA,
decreased from 70% to 51% in Canada, and
remained unchanged in the other geographic
areas (data not shown).
C. glabrata was least common as a cause of BSI
in Latin America (7.5%, range 0.0% to 12.2%) and
most common in Canada (20.1%) and the USA
(18.3%). Although there was no overall trend
towards an increase in the frequency of this
species as a cause of BSI over time (Table 1), the
frequency of BSI due to C. glabrata increased from
13% to 24% in Canada, from 11% to 13% in
Europe, and from 14% to 18% in the USA during
the 10-year period (data not shown).
C. parapsilosis was more common than C. glab-
rata as a cause of BSI in the European and Latin
American regions and was the third most com-
mon species in Asia-Paciﬁc, Canada and the USA.
C. parapsilosis was the most common BSI isolate in
Poland (33.3%) and Malaysia (48.6%). The fre-
quency of C. parapsilosis as a cause of BSI
decreased over time in Canada (18% to 8%),
Europe (20% to 11%), Latin America (45% to
13%) and the USA (24% to 11%).
Although C. tropicalis was the fourth most
common species overall (Table 1), it was equal
to or more common than C. glabrata and C.
parapsilosis in China, the Czech Republic, Poland,
Israel, Brazil, Chile, Colombia and Venezuela
(Table 2). C. tropicalis was the second most com-
mon BSI isolate overall in Latin America (21.3%)
and the frequency of this species as a cause of BSI
in Latin America increased from 10% to 24% over
the course of the study.
C. krusei was not a common cause of BSI
in most study sites; however, it accounted for
more than 10% of BSI in Slovakia (13.6%) and
Venezuela (12.2%) and was more common than
C. tropicalis in Australia, South Africa, France,
Slovakia, Spain and the United Kingdom. Candida
krusei did not appear to be increasing over time in
any of the areas studied.
Species distribution among the nine US census regions
Although several surveillance studies of candide-
mia have been conducted in the USA, they have
generally not been regionally comprehensive or
longitudinal [3,4,6,8,9,16,18]. Given the variation
in species distribution among candida BSI within
the broad geographic areas noted in Table 2 and
among individual institutions reported previ-
ously [33], it is reasonable to assume that regional
variation in species distribution and possibly
ﬂuconazole susceptibility, may exist among US
candida BSI isolates. To address the paucity of
published US regional surveillance data we have
stratiﬁed the 3683 US BSI isolates in the present
study according to the location of the submitting
institution in each of the nine US Bureau of the
Census regions (Table 3). A great deal of vari-
ation in species distribution among candida BSI
isolates was noted among the nine US census
regions. C. albicans was the predominant species
in all regions; however, it accounted for less than
50% of all candida BSI in region 1 (Paciﬁc,
48.7%), region 5 (East North Central, 47.6%) and
region 7 (New England, 47.0%) and for 60% or
greater in region 2 (Mountain, 64.5%), region 3
(West North Central, 60.6%) and region 6 (East
South Central, 61.7%). C. glabrata was the second
most common species in all regions with the
exception of region 4 (West South Central) where
it was superseded by C. parapsilosis. The highest
frequency of C. glabrata causing BSI was observed
in region 7 (New England, 37.3%) and the lowest
was in region 4 (West South Central, 11.7%).
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C. parapsilosis was the second most common BSI
isolate in regions 1 (Paciﬁc; tied with C. glabrata
at 18.5%) and 4 (West South Central), the third
most common in regions 5 (East North Central), 7
(New England), 8 (Mid-Atlantic) and 9 (South
Atlantic), and the fourth most common in regions
2 (Mountain), 3 (West North Central) and 6 (East
South Central). C. tropicalis accounted for
approximately 10% of candida BSI in all regions
with the exception of region 7 (New England,
4.8%). It was either the third or fourth ranked
species in all nine regions. C. krusei was the ﬁfth
most common species overall in the USA,
ranging from 0.7% of BSI in region 3 (West
North Central) to 5.6% in region 4 (West South
Central).
Trends in ﬂuconazole susceptibility in relation
to time, geographic location and species
of Candida in candidemia
Variation in ﬂuconazole susceptibility by species
and by year
The ﬂuconazole susceptibility proﬁle of all 6082
isolates of Candida spp. was 90% S, 7% S-DD
and 3% R with little variation over the 10-year
period (Table 4). A persistent and high level of
susceptibility to ﬂuconazole was observed for
C. albicans (89–100% S, 0–9% R), C. parapsilosis
(93–100% S, 0–2% R) and C. tropicalis (91–100%
S, 0–9% R). No trend toward greater resistance
to ﬂuconazole was observed among these species
over time.
Although C. glabratawas the least susceptible to
ﬂuconazole among the four most common species
of Candida causing BSI (61.4% S vs. 97.8–98.6% S),
a shift towards increased susceptibility from 1992
(15% S, 18% R) to 2000 (83% S, 5% R) was
observed. Although ﬂuconazole susceptibility
decreased somewhat in 2001 (64% S), the per cent
R remained low at 7%. This shift was observed in
all of the geographic areas and represented not
only an increase in the per cent S but a decrease in
the per cent R as well (Table 4).
Fluconazole susceptibility by geographic area
and by species
The overall susceptibility of candida BSI isolates
was greater than 90% for all geographic areas
(91–94% S, 2–3% R) with the exception of the
USA (88% S, 4% R) (Table 5). A high degree of
susceptibility was observed in all areas for C. alb-
icans (98–100% S, 0–2% R), C. parapsilosis (98–
100% S, 0–1% R) and C. tropicalis (94–100% S,
0–1% R). Fluconazole susceptibility among BSI
isolates of C. glabrata was highest in the Asia-
Paciﬁc region (76%) and lowest in the USA (58%
S). Rates of resistance among C. glabrata ranged
from 9% in the USA and Latin America to 2% in
the Asia-Paciﬁc region.
Fluconazole susceptibility by US census region
Among the 3683 candida BSI isolates from the
USA, ﬂuconazole susceptibility ranged from 85%
to 91% and resistance ranged from 1% to 5%
among the nine US census regions (Table 6).
C. albicans, C. parapsilosis and C. tropicalis were
all highly susceptible to ﬂuconazole (94–100% S,
0–3% R) with very little variation among the
different regions. Fluconazole susceptibility of
C. glabrata BSI isolates varied considerably among
the nine US census regions. Susceptibility was
lowest in region 1 (Paciﬁc, 38%) and region 6
(East South Central, 47%) and highest in region 4
(West South Central, 84%). The prevalence of
ﬂuconazole resistance among C. glabrata was
lowest in region 7 (New England, 0%) and was
highest in region 6 (East South Central, 23%).
Interestingly, there was little relationship between
the frequency of C. glabrata BSI in a given region
and the susceptibility of the isolates to ﬂucona-
zole. The most susceptible isolates were observed
in the regions with the lowest (region 4, 11.7%;
84% S, 5% R) and the highest (region 7, 37.3%;
71% S, 0% R) frequency of C. glabrata BSI isolates.
Notably, the three regions with the highest
prevalence of resistance to ﬂuconazole (regions
6, 8 and 9; 23%, 14% and 10% R, respectively)
were contiguous in the Southeast portion of US
(Fig. 1).
SUMMARY AND DISCUSSION OF
SURVEILLANCE DATA AND
SUGGESTIONS FOR FUTURE
INVESTIGATION
In this study we demonstrate important varia-
tions in the rank order and frequency of the
various species of Candida causing BSI over time
and by geographic area. An important observa-
tion was the high frequency of C. albicans as a
cause of BSI in many areas of the world.
C. albicans accounted for > 60% of BSI in 14 of
the 32 nations included in this study. Likewise,
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C. albicans was observed in > 60% of BSI in three
of the nine US census regions. Candida albicans
remains the most important aetiological agent of
candidemia worldwide.
C. glabrata also demonstrated an increase in
frequency over time as a cause of BSI in Canada,
the USA and in Europe, but was an infrequent
cause of BSI in Latin America and the Asia-Paciﬁc
Table 4. Fluconazole susceptibility over 10 years, 1992–2001a
Species Year
No.
tested
Cumulative percentage susceptible at MIC (lg ⁄mL)
0.12 0.25 0.5 1 2 4 8 16 32 64 128
C. albicans 1992 104 2 56 91 97 99 100 100b
1993 143 5 62 90 96 98 98 98b 98 98 98 99
1995 177 16 61 78 83 86 89 89b 91 91 92 92
1996 70 11 54 67 86 97 99 99b 99 99 99 99
1997 223 26 78 91 96 98 99 99b 99 99 99 99
1998 181 39 87 95 97 98 98 98b 99 99 99 99
1999 175 33 93 99 100 100 100 100b
2000 672 25 91 96 97 97 98 98b 99 99 99 99
2001 1656 14 80 94 98 99 99 99b 99 99 99 99
C. glabrata 1992 39 0 0 0 0 0 3 15b 59 82 85 92
1993 44 0 0 0 2 9 11 16b 75 89 93 98
1995 68 0 3 6 7 7 15 49b 82 85 90 96
1996 21 0 0 0 10 10 10 14b 86 86 86 91
1997 63 0 0 0 2 3 19 46b 89 92 97 98
1998 58 0 2 2 2 19 41 66b 91 95 95 100
1999 49 2 2 4 6 37 71 84b 94 96 98 100
2000 189 1 1 1 4 21 56 83b 91 95 97 99
2001 452 0 0 0 1 6 31 64b 91 93 95 99
C. parapsilosis 1992 51 0 4 35 71 94 98 98b 98 98 100
1993 77 0 5 30 60 92 96b 99 100
1995 30 0 3 43 63 83 87 93b 100
1996 14 0 14 50 64 93 93 93b 100
1997 78 3 19 64 82 96 99 100b
1998 47 0 19 66 92 98 100 100b
1999 33 0 24 67 91 97 100 100b
2000 170 0 11 51 83 92 98 100b
2001 296 0 5 43 79 92 96 99b 99 99 100
C. tropicalis 1992 28 0 11 50 89 96 96 100b
1993 39 0 5 36 77 92 95 97b 97 97 97 97
1995 38 5 16 61 87 95 95 95b 97 97 97 97
1996 21 0 5 48 62 91 91 91b 91 91 91 91
1997 29 0 31 45 83 97 100 100b
1998 28 0 43 75 93 96 96 100b
1999 38 11 48 90 90 95 95 97b 97 97 97 100
2000 146 1 21 55 88 96 97 97b 99 100
2001 218 0 11 35 68 93 98 99b 99 100
All speciesc 1992 235 1 27 55 70 78 80 83b 91 96 97 99
1993 315 2 30 53 68 80 82 84b 93 96 98 99
1995 332 9 35 54 61 67 71 78b 87 97 93 94
1996 133 6 32 49 64 77 78 79b 93 93 96 96
1997 413 14 48 64 73 79 83 89b 96 97 99 99
1998 328 21 55 69 76 83 87 92b 97 99 99 99
1999 320 20 61 75 79 85 92 94b 98 98 99 99
2000 1236 14 54 67 77 82 88 93b 96 97 99 99
2001 2770 8 50 65 74 79 85 91b 96 97 99 99
All organisms All years 6082 11 48 64 73 79 85 90b 95 97 98 99
aBroth microdilution testing according to NCCLS M27-A [42].
bPercentage of isolates susceptible to ﬂuconazole at the NCCLS breakpoint of £ 8 lg ⁄mL.
cIncludes C. krusei (153 isolates), C. lusitaniae (67 isolates), C. guilliermondii (48 isolates), C. famata (10 isolates), C. kefyr (10
isolates), C. pelliculosa (six isolates), C. lipolytica (four isolates), C. rugosa (ﬁve isolates), C. dubliniensis (three isolates),
C. inconspicua (three isolates), C. sake (two isolates) and one isolate each of C. lambica, C. norvegensis and C. zeylanoides.
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region. The frequency of C. glabrata as a cause of
BSI also varied widely among the nine USA
census regions. The highest proportion of BSI due
to C. glabrata overall was observed in New
England (region 7, 37.3%).
In contrast to C. albicans and C. glabrata,
C. parapsilosis appeared to be decreasing in fre-
quency as a cause of BSI in many areas of the
world including Canada, the USA, Latin America
and Europe. However, C. parapsilosis remained a
leading cause of BSI in several locations in Latin
America, the Asia-Paciﬁc region and in Europe. It
was the most common cause of candida BSI in
Malaysia (48.6%).
This study is the ﬁrst to provide regional
surveillance information on candida BSI in the
USA. As noted above, signiﬁcant variation in the
frequency and rank order of the different species
among the nine US census regions was observed,
with the greatest variation seen with C. glabrata
(Table 3).
Similar to the variation in species distribution
on a regional, national and international basis was
the variation in ﬂuconazole susceptibility and
resistance. Very little variation in ﬂuconazole
susceptibility was observed among BSI isolates
of C. albicans, C. parapsilosis and C. tropicalis. These
species accounted for 78% of all BSI and
remained highly susceptible (91–100% S) to ﬂuc-
onazole from 1992 until 2001, irrespective of
geographic origin. Rates of ﬂuconazole resistance
for these three species were usually £ 3%. In
Table 5. Fluconazole susceptibility by geographic area
Species Areab
No.
tested
Cumulative percentage inhibited at MIC (lg ⁄mL)a
0.12 0.25 0.5 1 2 4 8 16 32 64 128
C. albicans Asia-Pac. 324 9 76 93 98 99 99 99c 99 99 99 99
L. Am. 261 23 89 99 99 99 99 100c
Europe 446 33 89 97 98 99 99 99c 99 99 99 99
Canada 367 25 88 97 99 99 99 99c 99 99 99 100
USA 2003 15 76 91 95 97 98 98c 98 98 98 99
C. glabrata Asia-Pac. 45 0 0 0 0 2 44 76c 98 98 100
L. Am. 42 0 0 0 0 7 36 71c 88 91 93 98
Europe 100 1 1 1 1 9 29 61c 94 97 98 99
Canada 125 0 0 0 0 10 35 72c 91 94 98 98
USA 671 0 1 1 3 13 34 58c 86 91 93 98
C. parapsilosis Asia-Pac. 37 0 11 41 57 68 87 97c 97 97 100
L. Am. 99 2 10 43 67 85 98 100c
Europe 109 0 11 59 87 97 99 99c 100
Canada 64 0 8 56 86 94 98 100c
USA 487 0 9 45 78 95 97 98c 99 99 100
C. tropicalis Asia-Pac. 17 0 6 12 59 94 100 100c
L. Am. 119 1 16 46 81 96 97 99c 100
Europe 58 2 14 40 72 93 93 95c 98 100
Canada 37 0 27 49 81 100 100 100c
USA 354 1 19 53 80 94 97 98c 98 99 99 99
C. krusei Asia-Pac. 14 0 0 0 0 0 0 7 14 71 100
L. Am. 20 0 0 0 0 0 0 5 10 60 100
Europe 26 0 0 0 0 0 8 12 23 42 96 100
Canada 15 0 0 0 0 0 0 0 7 60 87 100
USA 78 0 0 0 0 0 0 3 21 62 100
All speciesd Asia-Pac. 441 6 58 73 80 84 90 94c 97 98 99 99
L. Am. 560 11 47 64 76 84 90 94c 96 98 99 99
Europe 775 19 55 68 76 81 85 90c 96 97 99 99
Canada 623 14 55 67 73 78 84 91c 96 98 99 99
USA 3683 8 45 62 72 78 83 88c 95 96 98 99
aBroth microdilution testing according to NCCLS M27-A [42].
bGeographic areas: Asia-Pac, Asia-Paciﬁc; USA, United States of America; L. Am., Latin America.
cPercentage of isolates susceptible to ﬂuconazole at the NCCLS breakpoint of £ 8 lg ⁄mL.
dIncludes C. lusitaniae (67 isolates), C. guilliermondii (48 isolates), C. famata (10 isolates), C. kefyr (10 isolates), C. pelliculosa
(six isolates), C. lipolytica (four isolates), C. rugosa (ﬁve isolates), C. dubliniensis (three isolates), C. inconspicua (three isolates),
C. sake (two isolates) and one isolate each of C. lambica, C. norvegensis and C. zeylanoides.
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contrast, the prevalence of ﬂuconazole resistance
among C. glabrata BSI isolates was quite variable
both over time and among the various countries
and regions. Surprisingly, the overall susceptibil-
ity of C. glabrata BSI isolates changed over time
with an increase in susceptibility and a decrease
in resistance since 1992 (Table 4). Resistance to
ﬂuconazole among C. glabrata isolates was gener-
ally greatest in the USA and varied by US census
region (Table 6). Interestingly, ﬂuconazole resist-
ance was not related to the frequency of C. glabrata
as a cause of BSI in the USA. The highest rates of
Table 6. Fluconazole susceptibility of candida bloodstream isolates in each of the nine US Bureau of the Census regions
Species Region
No.
tested
Cumulative percentage inhibited at MIC (lg ⁄mL)a
0.12 0.25 0.5 1 2 4 8 16 32 64 128
C. albicans 1 214 9 66 89 96 99 99 99b 99 99 99 99
2 168 19 77 89 94 96 97 97b 97 97 97 97
3 183 21 80 91 95 98 98 98b 98 98 98 98
4 92 20 85 92 96 96 98 98b 100
5 179 15 74 88 94 97 98 98b 99 99 99 99
6 58 10 85 100 100 100 100 100b
7 39 23 77 97 100 100 100 100b
8 376 18 78 89 93 95 95 96b 97 97 98 99
9 694 13 75 92 95 98 98 98b 99 99 99 99
C. glabrata 1 81 0 0 0 1 14 22 38b 79 93 95 98
2 40 0 3 5 8 13 35 68b 88 95 98 98
3 57 0 0 2 7 12 35 61b 95 95 97 100
4 19 0 0 0 5 47 74 84b 90 95 95 95
5 99 0 0 0 0 9 34 66b 91 92 95 100
6 17 0 0 0 0 18 29 47b 71 77 88 100
7 31 0 0 0 0 26 52 71b 100
8 138 0 2 4 6 12 34 60b 84 86 88 96
9 190 0 0 0 2 9 31 54b 84 90 93 98
C. parapsilosis 1 81 0 6 42 72 94 98 98b 99 99 100
2 12 0 17 42 83 100 100 100b
3 23 0 13 61 83 91 96 100b
4 22 0 5 64 96 100 100 100b
5 40 0 8 40 76 90 95 100b
6 4 0 25 75 100 100 100 100b
7 18 0 0 50 63 63 75 100b
8 126 0 14 53 87 99 99 100b
9 171 0 5 37 72 94 97 97b 99 100
C. tropicalis 1 42 0 12 57 76 88 95 98b 98 98 98 98
2 23 0 13 39 74 100 100 100b
3 32 0 19 72 91 94 97 97b 97 97 97 100
4 16 0 31 63 88 94 94 94b 94 100
5 35 3 23 54 77 91 94 97b 100
6 11 0 0 64 82 100 100 100b
7 4 0 50 75 100 100 100 100b
8 64 5 25 61 83 95 98 98b 100
9 127 1 17 43 77 93 96 97b 98 98 98 98
All species 1 439 4 35 57 69 78 81 85b 94 97 98 99
2 261 12 54 66 75 80 85 91b 95 96 97 97
3 302 13 52 69 76 81 85 91b 97 97 98 99
4 162 11 53 68 78 84 89 90b 94 98 99 99
5 376 7 39 53 63 69 76 86b 94 96 98 99
6 94 6 53 72 76 81 83 87b 94 95 98 100
7 83 11 39 54 58 68 78 88b 99 99 100
8 736 10 45 62 73 78 83 88b 94 95 97 99
9 1230 7 45 62 73 80 85 89b 95 97 98 99
aBroth microdilution testing according to NCCLS M27-A [42].
bPercentage of isolates susceptible to ﬂuconazole at the NCCLS breakpoint of £ 8 lg ⁄mL.
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susceptibility and lowest rates of resistance were
observed in the region with the highest frequency
of C. glabrata (region 7, 37.3%) as well as in the
region with the lowest frequency of C. glabrata
(region 4, 11.7%) (Tables 3 and 6).
The data presented herein raise several import-
ant issues for further investigation. First, it
appears that the forces causing variation in the
species of Candida causing BSI are more complex
than simple drug pressure [20]. Variables such as
patient age, underlying disease, location in hos-
pital, and local adherence to infection control
policies, as well as antifungal drug pressure, may
inﬂuence the frequency and rank order of Candida
species causing BSI [2,6,16,18,20,29,30,44]. The fact
that the US region with the highest frequency of
C. glabrata BSI also had the isolates of C. glabrata
least resistant to ﬂuconazole speaks directly
against simple drug pressure as the major cause
of the increased prevalence of C. glabrata in that
region. Several studies have made the observation
that the frequency of C. glabrata as an aetiological
agent of candidemia increases with increasing
patient age [6,29,30,45]. This association certainly
may be due to drug pressure or underlying
disease but one cannot discount the observations
of Lockhart et al. [46] who demonstrated in-
creased mucosal colonisation with C. glabrata
among healthy elderly individuals as evidence
of signiﬁcant change in the mucosal ﬂora with
age.
The observation of an increase in ﬂuconazole
susceptibility and a decrease in resistance over
time among C. glabrata BSI is perplexing. The fact
that all ﬂuconazole susceptibility testing was
performed in a central laboratory by the same
individuals using NCCLS reference methods
argues against ‘MIC creep’ as a result of variation
in MIC endpoint reading criteria being the cause
of this shift. Given the mechanism of ﬂuconazole
resistance known to occur in C. glabrata, induction
of CDR efﬂux pumps [34], one may hypothesise
that changes in drug pressure due to improved
ﬂuconazole utilisation practices (higher doses,
more focused risk-stratiﬁed patient selection)
may result in this type of change [32,33,47].
Unfortunately the data to support this hypothesis
are not readily available. Baddley et al. [48]
reported a stable rate of ﬂuconazole resistance of
approximately 10% among C. glabrata BSI, despite
a frequency of isolation ranging from 18% to 31%
over a 6-year period. Interestingly, Martins et al.
[49] reported a trend towards reduced rates of
carriage of ﬂuconazole-resistant C. albicans be-
tween 1995 and 1996 in a cohort of human
immunodeﬁciency virus-infected patients follow-
ing the introduction of highly active antiretroviral
therapy (HAART). The authors suggested that
decreased use of antifungal agents in patients
treated with effective antiretroviral therapy may
have contributed to the decrease in ﬂuconazole-
resistant strains colonising and infecting these
individuals [49]. Thus, similar observations to
those made in the present study have been
reported by other investigators for C. albicans as
well as C. glabrata. It may be that changes in the
overall ecology of Candida species occurred in the
past 10 years as a result of changes in overall
patterns of use for antifungals. At any rate,
these observations are intriguing and will re-
quire further study to determine the root causes
of this change in susceptibility. Regardless, it
appears that the susceptibility of candida BSI
isolates, including C. glabrata, has been stable at
least since 1992.
In summary, we have shown that the species
distribution of candida BSI isolates varies consid-
erably from region to region throughout the
world. C. albicans remains the predominant
pathogen in almost all areas and actually appears
to be stable or even increasing in frequency since
1992. Other observations include an increase in
the frequency of C. glabrata and a decrease in the
frequency of C. parapsilosis as aetiological agents
of BSI over time in most geographic regions.
Variability in the frequency of C. albicans and
C. glabrata as a cause of BSI is quite pronounced in
the different regions of the USA but this does not
seem to have a great effect on the activity of
ﬂuconazole. Fluconazole remains a highly effect-
ive agent against most major candida BSI isolates.
The documentation that resistance to ﬂuconazole
among C. glabrata varies by region in the USA and
is not directly related to the frequency of isolation
of C. glabrata is also of great interest. This
observation suggests that the emergence of C.
glabrata as a BSI pathogen is not entirely related to
antifungal drug pressure, although drug pressure
most likely plays a role in those regions where a
decreased susceptibility to ﬂuconazole among C.
glabrata BSI isolates has been documented. These
observations are generally encouraging relative to
the sustained usefulness of ﬂuconazole as a
systemically active antifungal agent for the treat-
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ment of candida BSI. However, they also make a
case for continued surveillance, especially on a
regional basis, in order to monitor pathogen
frequency and change in ﬂuconazole activity,
both overall and by speciﬁc pathogen.
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